Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.56 |
| ▸ | NOS3 | P29474 | 2/20 | 0.56 |
| ▸ | NOS1 | P29475 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | GLI1 | P08151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL998685 | 1.00 | NOS2 (0.56) | NOS2NOS3NOS1BLMGLI1 | |
| Proline SCHEMBL3987842 | 0.95 | NOS2 (0.56) | NOS2NOS3NOS1BLMGLI1 | |
| Proline SCHEMBL3987839 | 0.95 | NOS2 (0.56) | NOS2NOS3NOS1BLMGLI1 | |
| Proline SCHEMBL27997258 | 0.93 | NOS2 (0.54) | NOS2NOS3NOS1BLMGLI1 | |
| Pipecolic Acid SCHEMBL2263946 | 0.93 | NOS2 (0.48) | NOS2NOS3NOS1BLMGLI1 | |
| Proline SCHEMBL27694737 | 0.93 | NOS2 (0.52) | NOS2NOS3NOS1BLMGLI1 | |
| Proline SCHEMBL462226 | 0.93 | BLM (0.52) | NOS2NOS3NOS1BLMMEN1 | |
| Proline SCHEMBL10141185 | 0.93 | — | — | |
| Proline SCHEMBL462225 | 0.93 | BLM (0.52) | NOS2NOS3NOS1BLMMEN1 | |
| D-Proline SCHEMBL21462052 | 0.93 | BLM (0.52) | NOS2NOS3NOS1BLMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120575190-A | Method for synthesizing proline carbamate by catalyzing guanidine-based porous organic polymer | 广西师范大学 | 2025-09-02 | — | — | CN | disclosed |
| CN-120575190-A | Method for synthesizing proline carbamate by catalyzing guanidine-based porous organic polymer | 广西师范大学 | 2025-09-02 | — | — | CN | disclosed |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | SHIRE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2453900-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110209227-A1 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF BONE DISORDERS | TCP INNOVATIONS LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| US-7901873-B2 | Chemometric analysis which utilizes free proline as a diagnostic and prognostic indicator of conditions associated with low bone mineral density; osteoporosis | TCP INNOVATIONS LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| WO-2011007247-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC | 2011-01-20 | — | — | US | disclosed |
| US-20040241743-A1 | Methods for the diagnosis and treatment of bone disorders | TCP INNOVATIONS LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1384074-A2 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF BONE DISORDERS | Metabometrix Limited (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002086502-A2 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF BONE DISORDERS | METABOMETRIX LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | OPRL1, OPRM1, DNPEP | NOS2 213/4885NOS3 178/4885NOS1 192/4885 |
| US-20110209227-A1 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF BONE DISORDERS | SOST, PTH1R, COL2A1 | NOS2 1342/4885NOS3 533/4885NOS1 941/4885 |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | OPRL1, OPRM1, DNPEP | NOS2 332/4885NOS3 249/4885NOS1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.